Cytox has developed the groundbreaking variaTECT™ SNP research array for assessing Alzheimer’s disease risk. The variaTECT panel utilises the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform from Thermo Fisher Scientific. The array is easy to administer and simply requires genomic DNA, e.g. from a blood or saliva sample, clinical sample archive or biobanked DNA. Cytox offers genomic profiling testing assays and services globally to pharmaceutical and biotechnology companies and research laboratories pursuing clinical research and drug development.
Cytox welcomes enquiries from all organisations interested in our groundbreaking approach to identify an individual’s genetic risk component for developing Alzheimer's disease:
Please contact us via the contact form, on +44 (0) 1865 338 018 or at email@example.com